[Management of hyperphosphatemia in patients with chronic kidney disease]

Area of Science:

• Nephrology
• Biomaterials Science

Context:

• Hyperphosphatemia is prevalent in chronic kidney disease (CKD) patients, particularly those on hemodialysis.
• Elevated serum phosphorus is associated with significant cardiovascular morbidity and mortality in CKD.
• Current treatments for hyperphosphatemia, including dietary changes and phosphate binders, often fail to achieve target phosphorus levels.

Purpose:

• To investigate the efficacy of chitosan, a biocompatible polymer, as a phosphate-binding agent in a chewing gum formulation.
• To assess the potential of this novel chewing gum to manage hyperphosphatemia in CKD patients undergoing hemodialysis.

Summary:

• This study evaluated a chitosan-based chewing gum designed to bind dietary phosphates.
• Positive results were observed in CKD patients on hemodialysis, indicating a reduction in serum phosphorus levels.
• Salivary phosphate secretion was previously identified as a method to study phosphate balance in CKD.

Impact:

• The findings suggest a promising new therapeutic option for managing hyperphosphatemia in CKD patients.
• This approach may improve adherence and offer an alternative to conventional phosphate binders.
• Successful management of hyperphosphatemia could mitigate associated cardiovascular risks in the CKD population.